Exploration of VEGF expression in paediatric high grade glioma and diffuse intrinsic pontine glioma using 89Zirconium-bevacizumab imaged by PET

Recruiting

• Conditions: brainstem tumor; high grade glioma; 10029211

• Registration Number: NL-OMON38105
• Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- DIPG (MRI confirmed, biopsy not required) after radiotherapy
- De novo biopsy proven HGG with minimal residual tumor of 5 mm in each dimension
- pHGG & DIPG patients with progressive disease after radiotherapy
- Age between 4 and 18 years
- Able to lay down quiet for 30 minutes

Exclusion Criteria

- Chemotherapy or radiotherapy in the past two weeks
- Previous administration of bevacizumab or another anti-VEGF drug
- Known hypersensitivity against humanized monoclonal antibodies
- Neurofibromatosis type I

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>VEGF-expression measured by Standard Uptake Values of 89Zr-Bevacizumab in pHGG<br /><br>and DIPG</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Optimal moment of scanning obtained by five patients with positive<br /><br>89Zr-bevacizumab uptake<br /><br>- Body biodistribution and dosimetry of 89Zr-bevacizumab</p><br>